TruAlt Bioenergy share price today

TruAlt Bioenergy Ltd's share price was ₹369.45 at the close on 4 November 2026. It has been falling for 10 weeks. That is 16.8% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹320 and ₹532, and at that close it sat 23% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today TruAlt Bioenergy Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 2 weeks running.

Over the last 1 year the share price moved −30% while the NIFTY 500 moved −5%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 23 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

One change stood out: operating margin up 16 points on a year earlier.

1. Operating margin up 16 points on a year earlier

   12% in the September 2026 quarter, from -4%.

For July to September 2026 (the quarter ended 30 September 2026), TruAlt Bioenergy reported revenue of ₹811 crore, up 605.2% from ₹115 crore a year earlier, and a profit of ₹35.0 crore, against a loss of ₹38.0 crore a year earlier.

TruAlt Bioenergy results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

TruAlt Bioenergy's management discussed these results on a call held on 26 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

TruAlt Bioenergy closed at ₹369.45 on 4 November 2026, down 12.7% from ₹423.20 a year earlier (7 November 2025). Its highest weekly close since October 2025 was ₹531.95 on 9 June 2026.

TruAlt Bioenergy share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

64 weekly closes from 3 October 2025 to 4 November 2026.

4 Nov 2026: TruAlt Bioenergy closed at ₹369.45, up 2.7% on the week and down 16.8% on the month. 26 Oct 2026: TruAlt Bioenergy held its results call for July to September 2026. Management guided: Average ethanol utilization planned at 75-80% going forward.

Earlier

• Results for July to September 2026: Revenue up 605.2% on a year earlier.

TruAlt Bioenergy has paid no dividend on the NSE since its first NSE close in our records (3 October 2025), the start of the period we checked.

No. TruAlt Bioenergy Ltd paid out 0% of its profit as dividends in each of its last 4 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 26 October 2026, TruAlt Bioenergy's management guided: Average ethanol utilization planned at 75-80% going forward.

“We have already received an incentive of approximately 150 crores as viability gap funding under the PM JI-VAN Yojana for the proposed plant.”Vijay Nirani, on the call for July to September 2026

What management guided

• Ethanol volume: 8.5 crore litres cited in hand, later 4.5 crore still due; 6-7 crore more expected in Nov-Dec; ESY26-27 allocation at least 40-42 crore litres versus approximately 66 crore eligible; first figures unreconciled.
• FY27 blended ethanol realization estimated at ₹64-65/litre versus ₹67 in prior years; average operating margin may be 1-2% below achieved levels.
• Two further Sumitomo plants expected this quarter, taking CBG capacity to approximately 72 TPD; construction planned for six GAIL units.
• CBG pipeline visibility of 250 TPD; revenue approximately ₹20 crore over the next two quarters and operating margin expected at 50-55%.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 26 October 2026.

When TruAlt Bioenergy reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Check whether pending ethanol supply clears and fresh OMC allocations translate into lifting rather than inventory accumulation.

TruAlt Bioenergy is not on any of our India lists this week.

TruAlt Bioenergy Ltd earned ₹35.0 Cr of net profit in the Sep 2026 quarter. Full-year FY26 profit was ₹97.0 Cr. Over 3 years profit has grown 40.5% a year on average. That is 4.3% of the quarter's revenue. The same quarter a year earlier lost ₹38.0 Cr. 3 of the last 10 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹97.0 Cr (−34.0% on the year before).

On average over the last four quarters, profit changed +344.5% and revenue +187.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

TruAlt Bioenergy Ltd reported ₹811 Cr of revenue in the Sep 2026 quarter, +605.2% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 3 years it has grown 31.4% a year on average. The last full year, FY26, came in at ₹1,728 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹2,747 Cr.

FY26 revenue was ₹1,728 Cr, −9.4% on the year before.

Recent pace: the last four quarters grew +187.3% on average, against 31.4% a year over the longer run, so this year is growing faster than its own long-run rate.

TruAlt Bioenergy Ltd's operating margin was 12.0% in the Sep 2026 quarter, 16.0 percentage points higher than the same quarter a year ago. Across 4 years it has been between 14.0% and 17.0%. The latest quarter is below every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +16.4 percentage points on the year while gross margin changed +4.3 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 29% of TruAlt Bioenergy Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 its operations used ₹296 Cr of cash, against ₹97.0 Cr of profit. After ₹510 Cr of spending on assets, free cash was −₹806 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 29% of profit came in as cash: the cash cycle got 242 days longer between FY23 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 242 days longer. The next section looks at where the cash is stuck.

TruAlt Bioenergy Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 170 days in FY26, up from −72 days in FY23. It spent ₹1,151 Cr on assets over the last 3 years. Customers take 86 days to pay, and stock sits for 173 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹1,728 Cr, each day of that cycle ties up about ₹4.7 Cr, so roughly ₹805 Cr is tied up in the business at any time.

FY26: customers took 86 days to pay and stock sat for 173 days, about 5.7 months of sales sitting as stock, for a full cycle of 170 days, longer than FY23's −72.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 173 days. Customers pay about 86 days after that. Suppliers are paid at 89 days. Together that makes the 170-day cycle.

Spending on assets: ₹1,151 Cr over the last 3 years, against ₹210 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹68.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

TruAlt Bioenergy Ltd's P/E is 13.8×, about the lowest it has ever been. Its usual P/E (the middle reading) is 24.1×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved −46.1% while the price moved −12.7%. The price did better than earnings, which pushed the multiple up within its own range.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

TruAlt Bioenergy Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 7 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

TruAlt Bioenergy Ltd earned a ROCE of 10% in FY26. Its return on capital used (ROIC) is 2.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 5.6% net margin and 0.46× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 5.6% net margin × 0.46× asset turnover × 2.48× leverage (assets divided by equity) ≈ 6.4% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 9.1% − 12.0% = −2.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

The 9.1% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 5.7%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

TruAlt Bioenergy Ltd has total debt of ₹1,663 Cr against shareholder equity of ₹1,687 Cr as of Sep 2026, so its debt is 0.99× its equity. Year by year, that ratio went from 2.02 in FY25 to 1.05 in FY26. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

No group of TruAlt Bioenergy Ltd's owners changed its stake by a full percentage point over the last 4 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

For TruAlt Bioenergy Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

54.1 out of 100, rank 11 of 42 in Miscellaneous, with 68% of the evidence available.

TruAlt Bioenergy Ltd scores 54.1 out of 100 against the 42 companies it is compared with in Miscellaneous, ranking 11. Earnings are strong; relative strength in its sector is -12% and the one-year return is -19.4%.

The four parts add up to the total exactly: 25.9 + 10.5 + 11.1 + 6.6 = 54.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

TruAlt Bioenergy ranks 11 of 42 Miscellaneous companies on the 4-Factor Sector Score, with 54.1 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Miscellaneous, all 42 compared on one page.

TruAlt Bioenergy is the 11th largest of 42 Miscellaneous companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Kaveri Seed Company, RattanIndia Enterprises and Anzen India Energy Yield Plus Trust. Just below it: Lords Mark Industries, Eveready Industries India and Delta Corp.

Miscellaneous companies close in size

8. Kaveri Seed Company Ltd ₹3,390 crore
9. RattanIndia Enterprises Ltd ₹3,261 crore
10. Anzen India Energy Yield Plus Trust ₹3,171 crore
11. TruAlt Bioenergy Ltd ₹3,084 crore
12. Lords Mark Industries Limited ₹3,079 crore
13. Eveready Industries India Ltd ₹2,257 crore
14. Delta Corp Ltd ₹1,986 crore

All 42 Miscellaneous companies, largest first

Companies close in size in other industries

1025. Styrenix Performance Materials Ltd ₹3,087 crore · Petrochem - Polymers
1026. Bajaj Electricals Ltd ₹3,085 crore · Domestic Appliances
1027. TruAlt Bioenergy Ltd ₹3,084 crore
1028. Lords Mark Industries Limited ₹3,079 crore · Miscellaneous
1029. Solara Active Pharma Sciences Ltd ₹3,070 crore · Pharma - API & CRAMS

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.